Jeffrey Deitch, DO
Family Medicine · Sterling Heights, MINPI 1386634749
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,380 of the $196,767 with a category attached, or 70.3%. It is spread thinly across 49 manufacturers, the largest accounting for just 18.6%. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,020 payments — averaging $192.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$37K
- Otsuka America Pharmaceutical, Inc.$34K
- Teva Pharmaceuticals USA, Inc.$31K
- Johnson & Johnson$28K
- Sunovion Pharmaceuticals Inc.$26K
- Urovant Sciences Inc$19K
- plus $23K from 43 others
Across 7 payments — averaging $3371.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$14K
- Sanofi US Services Inc.$10K
What the payments were for
- Consulting fees$3,9072%
- Speaking & faculty fees$138,38070%
- Travel & lodging$36,92419%
- Food & beverage$17,3519%
- Education$2050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$33,209
- GEMTESA$31,176
- EZALLOR SPRINKLE$30,268
- Austedo XR$29,825
- KAPSPARGO$27,490
- DRIZALMA SPRINKLE$27,240
- XARELTO$27,101
- LONHALA MAGNAIR$24,843
- AIRSUPRA$125
- EVENITY$125
- Ozempic$125
- NUEDEXTA$122
How this compares
$196,767 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 249 | $172,303 |
| OzempicSemaglutide | 89 | $115,106 |
| MounjaroTirzepatide | 53 | $80,591 |
| JardianceEmpagliflozin | 58 | $68,309 |
| TrulicityDulaglutide | 37 | $61,190 |
| JanuviaSitagliptin Phosphate | 52 | $37,477 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $36,728 |
| XareltoRivaroxaban | 25 | $35,708 |
| SympazanClobazam | 15 | $28,939 |
| LivaloPitavastatin Calcium | 15 | $15,190 |
| Repatha SureclickEvolocumab | 11 | $14,659 |
| Incruse ElliptaUmeclidinium Bromide | 26 | $9,418 |
| EntrestoSacubitril/Valsartan | 13 | $9,143 |
| Pitavastatin Calcium | 20 | $8,529 |
| Atorvastatin Calcium | 531 | $7,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $755 | $172,303249 claims |
| Lilly USA, LLCMounjaro, Trulicity | $615 | $141,78190 claims |
| Novo NordiskOzempic | $1,913 | $115,10689 claims |
| Boehringer IngelheimJardiance | $805 | $68,30958 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arexvy | $247 | $50,03083 claims |
| MerckJanuvia | $115 | $37,47752 claims |
| Johnson & JohnsonXarelto | $27,844 | $35,70825 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $118 | $15,19015 claims |
| NovartisEntresto | $400 | $9,14313 claims |
| AbbVieSynthroid | $670 | $2,52222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Sterling Heights
- Steven MargolisSterling Heights$90K
- Mark RosenbergSterling Heights$17K
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.